Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66134 | 1.00 | GPR119 (0.48) | GPR119HPGDPIK3CDRECQLEPHX1 | |
| SCHEMBL330785 | 1.00 | GPR119 (0.48) | GPR119HPGDPIK3CDRECQLEPHX1 | |
| SCHEMBL5538557 | 0.94 | GPR119 (0.45) | GPR119HPGDPIK3CDRECQLEPHX1 | |
| SCHEMBL731800 | 0.91 | MEN1 (0.49) | GPR119HPGDEPHX1USP30MEN1 | |
| SCHEMBL215721 | 0.91 | MEN1 (0.49) | GPR119HPGDEPHX1USP30MEN1 | |
| SCHEMBL215720 | 0.91 | MEN1 (0.49) | GPR119HPGDEPHX1USP30MEN1 | |
| SCHEMBL57106 | 0.91 | GPR119 (0.53) | GPR119HPGDRECQLEPHX1USP2 | |
| SCHEMBL9938442 | 0.90 | HPGD (0.49) | GPR119HPGDRECQLEPHX1USP30 | |
| SCHEMBL31045719 | 0.89 | HPGD (0.51) | GPR119HPGDEPHX1USP30MEN1 | |
| SCHEMBL20389199 | 0.88 | GPR119 (0.44) | GPR119HPGDPIK3CDRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102531987-B | (S) synthetic method of 3 amino-pyrrolidine dihydrochlorides | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-12-14 | — | — | CN | claimed |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-26 | — | — | US | disclosed |
| CN-122070277-A | Androgen receptor PROTAC | 葛兰素史密斯克莱知识产权发展有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035358-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3891149-B1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| EP-0597821-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1994-05-18 | — | — | EP | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| US-5124460-A | Enantioselective synthesis of 3-substituted 1-azabicyclo (2.2.1)heptanes | MERCK SHARP & DOHME LTD. (GB) | 1992-06-23 | — | — | US | disclosed |
| US-5106853-A | Selective muscarinic agonist | MERCK SHARP & DOHME, LTD. (GB) | 1992-04-21 | — | — | US | disclosed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| US-5102877-A | Carbapenicillin antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0456310-A2 | Enantioselective synthesis of 3-substituted 1-azabicyclo [2.2.1]heptanes | MERCK SHARP & DOHME LTD. (GB) | 1991-11-13 | — | — | EP | disclosed |
| EP-0398629-A2 | An oxadiazole and its salts, their use in treating dementia, their preparation and formulations | MERCK SHARP & DOHME LTD. (GB) | 1990-11-22 | — | — | EP | disclosed |
| EP-0394991-A1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | AR, CRBN, PSMA3 | GPR119 1138/4885HPGD 3934/4885PIK3CD 3090/4885 |
| US-20260035358-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | CRBN, WEE1, WEE2 | GPR119 3117/4885HPGD 4861/4885PIK3CD 1023/4885 |
| US-12577231-B2 | Androgen receptor PROTACS | AR, CRBN, PSMA3 | GPR119 1138/4885HPGD 3934/4885PIK3CD 3090/4885 |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | GPR119 397/4885HPGD 2784/4885PIK3CD 979/4885 |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX7 | GPR119 910/4885HPGD 1820/4885PIK3CD 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.